Investment Team
Partner, Head of Technology Mid-Cap
Charles-Hubert Le Baron joined Astorg in 2011 and transitioned to the Mid-Cap Fund in 2020, after working with the Flagship team. In 2024, he was appointed Head of Technology & Software for the Mid-Cap Fund and serves as an observer on the Mid-Cap Investment Committee.
Since joining Astorg, he has been involved in several key investments, including Sebia, HRA Pharma, Opus 2, Armor-IIMAK, Sofico, and Redslim.
Prior to joining Astorg, Charles-Hubert worked in the Transaction Advisory division at Ernst & Young in Paris, where he conducted financial due diligence across the aerospace, consumer goods, payment services, and energy sectors.
Charles-Hubert is based in London and is a graduate of École des Mines de Paris.
Redslim
Redslim is the leading global data management and integration platform focused on Consumer-Packaged Goods (CPG) and Consumer Healthcare (CHC) end markets
Investment year: 2025
Tech In Portfolio
Sofico
Sofico is a leading global provider of leasing software solutions for the automotive market.
Investment year: 2024
Tech In Portfolio
ARMOR-IIMAK
Armor IIMAK is the global leader in thermal transfer ribbons, which are inked films used as consumables for the thermal transfer printing industry.
Investment year: 2022
Industrials In Portfolio
Opus 2
Opus 2 is the leading provider of integrated software and services for the global legal disputes market.
Investment year: 2021
Tech In Portfolio
HRA Pharma
HRA is an innovative OTC pharma company with leading positions in Europe and in the US.
Investment year: 2016
Healthcare Realised
M7 Group
M7 is a major European pay-tv operator offering language-specific packages to subscribers across Europe.
Investment year: 2014
Tech Realised
Saverglass
Saverglass is the world leader in the design and manufacturing of high quality glass bottles for spirits and fine wines.
Investment year: 2011
Industrials Realised
Sebia
Founded in 1967, SEBIA is a world’s leading provider of clinical protein electrophoresis equipment and reagents, a technology used for in-vitro diagnostics (IVD) testing.
Investment year: 2001
Healthcare Realised